Latest news with #EnlivexTherapeutics
Indianapolis Star
2 days ago
- Business
- Indianapolis Star
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire RedChip Companies will air interviews with Enlivex Therapeutics (NASDAQ:ENLV) and Foremost Clean Energy (Nasdaq:FMST) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, June 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: In an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Enlivex is pioneering macrophage reprogramming immunotherapy with its Allocetra™ platform, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. This innovative approach aims to address critical medical challenges, including debilitating diseases like osteoarthritis. In 2024, the company achieved a significant milestone with the initiation of a multi-country, randomize, double -blind, placebo-controlled Phase I/II trial evaluating Allocetra™ in up to 160 patients with moderate to severe knee osteoarthritis. With promising data from the open-label Phase 1 stage of the trial the company had completed the enrollment of 134 patients for the Phase 2 stage and expecting knee osteoarthritis key data by August 2025, potentially paving the way for future therapeutic breakthroughs. Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share the company's strategic vision for advancing uranium exploration in the world-renowned Athabasca Basin. Barnard details Foremost's expansive portfolio of 10 uranium properties spanning over 330,000 acres, including high-priority drill targets at Hatchet Lake and Murphy Lake South, where recent assays confirm strong mineralization and discovery potential. He also discusses the company's transformational partnership with Denison Mines, which brings technical, financial, and strategic backing from a C$2.9 billion uranium leader with a 19.13% equity stake in Foremost. With nuclear energy gaining momentum as a critical clean power source – and global pledges to triple capacity by 2050 – Foremost is uniquely positioned to benefit from structural supply deficits and surging demand. Barnard highlights the company's fully funded 2025 exploration program, robust institutional backing, and dual exposure to uranium and lithium as key drivers of long-term shareholder value. ENLV and FMST are clients of RedChip Companies. Please read our full disclosure at About Enlivex Therapeutics Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit About Foremost Clean Energy Foremost Clean Energy Ltd. (NASDAQ:FMST)(CSE:FAT)(WKN:A3DCC8) is a rapidly growing North American uranium and lithium exploration company. The Company holds an option to earn up to a 70% interest in 10 prospective uranium properties (with the exception of the Hatchet Lake, where Foremost is able to earn up to 51%), spanning over 330,000 acres in the prolific, uranium-rich Athabasca Basin region of northern Saskatchewan. As the demand for carbon-free energy continues to accelerate, domestically mined uranium and lithium are poised for dynamic growth, playing an important role in the future of clean energy. Foremost's uranium projects are at different stages of exploration, from grassroots to those with significant historical exploration and drill-ready targets. The Company's mission is to make significant discoveries alongside and in collaboration with Denison through systematic and disciplined exploration programs. Foremost also has a portfolio of lithium projects at varying stages of development, which are located across 55,000+ acres in Manitoba and Quebec. For further information, please visit the Company's website at About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: 'Discovering Tomorrow's Blue Chips Today'™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave Gentry RedChip Companies Inc. 1-407-644-4256 info@ SOURCE: RedChip Companies, Inc. View the original press release on ACCESS Newswire
Business Insider
03-05-2025
- Business
- Business Insider
Enlivex Therapeutics files $300M mixed securities shelf
17:12 EDT Enlivex Therapeutics (ENLV) files $300M mixed securities shelf Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
07-04-2025
- Business
- Yahoo
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. Given this risk, we thought we'd take a look at whether Enlivex Therapeutics (NASDAQ:ENLV) shareholders should be worried about its cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In December 2024, Enlivex Therapeutics had US$23m in cash, and was debt-free. Importantly, its cash burn was US$13m over the trailing twelve months. That means it had a cash runway of around 22 months as of December 2024. Notably, analysts forecast that Enlivex Therapeutics will break even (at a free cash flow level) in about 5 years. That means unless the company reduces its cash burn quickly, it may well look to raise more cash. You can see how its cash balance has changed over time in the image below. Check out our latest analysis for Enlivex Therapeutics Because Enlivex Therapeutics isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Even though it doesn't get us excited, the 45% reduction in cash burn year on year does suggest the company can continue operating for quite some time. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . While Enlivex Therapeutics is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Enlivex Therapeutics has a market capitalisation of US$21m and burnt through US$13m last year, which is 62% of the company's market value. That's very high expenditure relative to the company's size, suggesting it is an extremely high risk stock. Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought Enlivex Therapeutics' cash burn reduction was relatively promising. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Even though we don't think it has a problem with its cash burn, the analysis we've done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future. Separately, we looked at different risks affecting the company and spotted 4 warning signs for Enlivex Therapeutics (of which 1 makes us a bit uncomfortable!) you should know about. Of course Enlivex Therapeutics may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
